Table 1.
The majority of TNBC cell lines are sensitive to combined treatment with metformin and BMS-754807
| Cell line | TNBC subtype | ED50 BMS (μM) | ED50 Metformin (mM) | CI Value | Effect |
|---|---|---|---|---|---|
| BT-20 | LAR Unclassified | 5.41 | 1.08 | 0.43 | Synergism |
| MDA-MB-453 | LAR LAR | 45.9 | 0.9 | 0.43 | Synergism |
| HCC1806 | Basal-like BL2 | 7.69 | 2.56 | 0.49 | Synergism |
| MDA-MB-436 | Mesenchymal-like MSL | 2.34 | 0.23 | 0.56 | Synergism |
| HCC70 | Basal-like BL2 | 1.16 | 5.82 | 0.59 | Synergism |
| MDA-MB-231 | Mesenchymal-like MSL | 3 | 15.33 | 0.63 | Synergism |
| MDA-MB-468 | Basal-like BL1 | 0.39 | 0.16 | 0.63 | Synergism |
| HCC1937 | Basal-like BL1 | 10.42 | 2.08 | 0.75 | Synergism |
| HCC38 | Basal-like BL1 | 0.95 | 1.9 | 0.75 | Synergism |
| MDA-MB-157 | Mesenchymal-like MSL | 3.29 | 0.55 | 0.92 | Synergism |
| BT-549 | Mesenchymal-like M | 5.09 | 12.73 | 0.93 | Synergism |
| Hs 578T | Mesenchymal-like MSL | 4.32 | 11.52 | 1.03 | Additive |
| HCC1395 | LAR Unclassified | 29.5 | 31.1 | 1.28 | Antagonism |
All the cells were cultured in regular growth medium for 24 hours and then treated with increasing concentrations of either a single agent or both agents for 72 hours. CI values were calculated by software CompuSyn to determine the anticancer effect of drug combination. The concentration of each drug at ED50 were given by the report from the software CompuSyn.